Shilpa Medicare
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Shilpa Medicare is strategically transitioning from a generic API manufacturer to a high-value CDMO and specialty pharmaceutical player, as highlighted by management's focus on commercializing a robust pipeline of complex formulations and biologics. This transformation is supported by significant investments in manufacturing infrastructure, which positions the company to capitalize on the growing demand for outsourced pharmaceutical services. Vista's financial outlook reflects stable revenue growth, driven by the successful scaling of biologics and proprietary technologies, alongside improving margins as operational efficiencies are realized. The anticipated 15% CAGR in revenue from FY25 to FY28 underscores the potential for multi-year earnings growth, particularly with key catalysts like the commissioning of the Dharwad biologics facility. However, challenges such as regulatory risks and geopolitical uncertainties remain pertinent. Overall, Shilpa Medicare's strategic initiatives align well with Vista's forecast, which anticipates a fair valuation with an expected upside of approximately 17.4%. Over the next 12-24 months, the company should focus on scaling existing capacities and advancing its biosimilar pipeline while navigating potential headwinds from regulatory complexities and market competition
Why We Like This Stock
- Management's focus on high-margin specialty products and biologics is expected to drive revenue growth
- Significant investments in manufacturing infrastructure enhance Shilpa's competitive position in the CDMO market
- A diversified product pipeline provides clear revenue visibility and supports long-term earnings growth
Things To Watch Out For
- Regulatory risks and execution challenges in scaling biologics and CDMO segments could impact growth
- Geopolitical uncertainties may affect export opportunities and partnerships
- Dependence on partner-led commercialization poses risks to revenue realization
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 1,146 | 1,281 | 1,539 | 1,810 | 2,122 |
| Profit Before Tax (Cr.) | 47 | 146 | 283 | 343 | 399 |
| PBT Margin | 4.1% | 11.4% | 18.4% | 18.9% | 18.8% |
| Net Profit (Cr.) | 8 | 59 | 239 | 288 | 335 |
| Earnings Per Share | 0.4 | 3.0 | 12.2 | 14.7 | 17.1 |
Analyst Recommendations
No analyst recommendations available.
Company Overview
Show Company Profile
Shilpa Medicare Limited offers pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, and contract development and manufacturing organisation (CDMO) services in India, the United States, Europe, and internationally. The company offers various oncology and non-oncology APIs, such as anastrozole, acebrophylline, ambroxol hydrochloride, axitinib, azacitidine, abiraterone acetate, bendamustine HCL monohydrate, bicalutamide, bortezomib, busulphan, cabazitaxel amorphous, capecitabine, clofarabine, cyclophosphamide, dasatinib, decitabine, dimethyl fumarate, erlotinib HCL, enzalutamide, fingolimod hydrochloride, gemcitabine HCl, ibrutinib, imatinib mesylate, irinotecan HCl trihydrate, lenalidomide, lenvatinib mesylate, letrozole, and melphalan HCL. It also provides nifedipine, oxaliplatin, pazopanib, pemetrexed disodium hemipentahydrate, pemetrexed dipotassium nonahydrate, pirfenidone, pomalidomide, sodium cholesteryl sulfate, sorafenib tosylate, sunitinib malate, temozolomide, teriflunomide, thalidomide, tranexamic and zoledronic acid, phenylephrine, citicholine, palbocicilib, nilotinib, nintedanib, praziquintol, carmustine, elthrombopag olamine, abacavir sulphate, tenofovir disproxyl fumarate API, tenofovir alfanamide, prucalopride succinate, and varenicline tartrate. In addition, the company offers GLP-1; HpAPI; intermediates; peptides; payloads and linkers; biopolymers; microbial and mammalian products; fermentation; small molecules; monoclonal antibodies and recombinant technology; and tablets, capsules, injectables, oral dissolving films, and transdermal patches. Further, it engages in wind power generation activities. The company serves wholesalers, distributors, doctors, pharmacy chain NGOs, hospitals, government institutions, and companies. The company was formerly known as Shilpa Antibiotics Ltd and changed its name to Shilpa Medicare Limited in February 2003. Shilpa Medicare Limited was incorporated in 1987 and is based in Raichur, India.